Back To Search Instructions
Protocols
10 protocol(s) meet the specified criteria
PI: Van Le, Linda
Protocol No.TitleStatus
GOG-0225Can Diet and Physical Activity Modulate Ovarian, fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?Open
GOG-0258A Randomized Phase III Trial Of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma Open (affiliates only)
GOG-0263Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic LyphadenectomyOpen
GOG-0264A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary Open
GOG-0281 A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal CancerOpen
GOG-286BA Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial CancerOpen
GOG212A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) (IND # 70177), Versus No Treatment Until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer Who Acheive a Complete Clinical Response to Primary Platinum/Taxane ChemotherapyOpen (affiliates only)
GOG3005-M13-694A Phase 3 Placebo-controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serious Epithelial Ovarian, Fallopian tube, or Primary Peritoneal Cancer (M13-694 Protocol)Open
MORAB-003-011A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian CancerOpen
NRG-GY004A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal CancerOpen